Which statement best describes the current evidence-based recommendation for Lactobacillus GG use in children?

Which statement best describes the current evidence-based recommendation for Lactobacillus GG use in children?

• A. Safe and effective for acute infectious diarrhea
• B. Not safe for children
• C. Therapy for NEC
• D. Eradicate Helicobacter pylori

Answer: (A)

Lactobacillus rhamnosus GG is a probiotic with the strongest pediatric evidence for use in acute infectious diarrhea. When given alongside standard food and fluid replacement, it can modestly shorten the course of diarrhea and reduce stool frequency in children. This benefits comes from the probiotic’s ability to help restore the balance of gut microbiota, reinforce the mucosal barrier, and modulate the local immune response, which supports quicker recovery from gastroenteritis. Safety is a major plus in healthy children; Lactobacillus GG is generally well tolerated with rare serious adverse events. Caution is advised in certain high-risk groups, such as severely immunocompromised individuals or those with central venous catheters, where the risk–benefit must be weighed. It isn’t used as a therapy for NEC, nor is it a strategy for eradicating Helicobacter pylori. While some probiotics have roles in certain neonatal NEC prevention scenarios, LGG’s established use in children is for acute infectious diarrhea, making it the best-supported option among the statements.

Lactobacillus rhamnosus GG is a probiotic with the strongest pediatric evidence for use in acute infectious diarrhea. When given alongside standard food and fluid replacement, it can modestly shorten the course of diarrhea and reduce stool frequency in children. This benefits comes from the probiotic’s ability to help restore the balance of gut microbiota, reinforce the mucosal barrier, and modulate the local immune response, which supports quicker recovery from gastroenteritis.

Safety is a major plus in healthy children; Lactobacillus GG is generally well tolerated with rare serious adverse events. Caution is advised in certain high-risk groups, such as severely immunocompromised individuals or those with central venous catheters, where the risk–benefit must be weighed.

It isn’t used as a therapy for NEC, nor is it a strategy for eradicating Helicobacter pylori. While some probiotics have roles in certain neonatal NEC prevention scenarios, LGG’s established use in children is for acute infectious diarrhea, making it the best-supported option among the statements.